Furmonertinib用于非小细胞肺癌的I 期研究｜NCT05364073

一分钟看懂

这是一项关于非小细胞肺癌的I 期研究，登记的药物或干预包括Furmonertinib，当前状态为研究进行中，已停止招募。登记地点显示中国合肥、北京、朝阳、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Furmonertinib · I 期

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

* Histologically or cytologically documented, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
* Disease that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable; or for whom a clinical trial of an investigational agent is a recognized standard of care.
* Documented radiologic disease progression during or after the last systemic anti-cancer therapy before the first dose of furmonertinib.
* For patients with Epidermal Growth Factor Receptor (EGFR) mutations sensitive to osimertinib, the patient must have received osimertinib prior to study enrollment in regions where osimertinib is approved, including the US.
Stage 1 dose escalation and backfill cohorts and Stage 2 Cohorts 1, 2, 3 and 4:
-Patients with CNS metastases (including leptomeningeal disease) may be eligible if meeting additional protocol specified criteria.
Stage 1 Dose Escalation and Backfill Cohorts Inclusion Criteria:
\- Documented validated results from local testing of tumor tissue or blood confirming the presence of an activating, including uncommon, EGFR mutation or HER2 exon 20 insertion mutation performed at a CLIA-or equivalently certified laboratory.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT05364073；登记信息更新于 2026-03-13。